Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 1, 2003, Pages 13-18

  Santoso, Joseph T ^a   Lucci III, Joseph A ^b   Coleman, Robert L ^c   Schafer, Ilona ^b   Hannigan, Edward V ^b  

^a UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cisplatin nephrotoxicity; Furosemide; Hydration; Mannitol

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CEPHALOSPORIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FUROSEMIDE; GRANISETRON; MANNITOL; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; SODIUM CHLORIDE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; CREATININE; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; FUROSEMIDE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; MANNITOL; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; SODIUM CHLORIDE;

EID: 0043172250     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0620-1     Document Type: Article

References (28)

1. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339-1348
2. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137-1143
3. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144-1153
4. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154-1161
5. Peters WA III, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS (2000) Concurrent chemotherapy and pelvic radiation therapy as adjunctive therapy after radical surgery in high risk early stage carcinoma of the cervix. J Clin Oncol 18:1606-1613
6. Ozols RF, Young RC (1985) High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12:21-30
7. Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin (review). Gynecol Oncol 50:147-158
8. Daugaard G, Abildgaard U, Larsen S (1987) Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol 10:54-64
9. Clayton DA, Doda JN, Fiedberg ED (1974) The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria. Proc Natl Acad Sci U S A 71:2777-2781
10. Gordon JA, Gattone VH (1986) Mitochondrial alteration in cisplatin-induced acute renal failure. Am J Physiol 250:F991-998
11. Tisher CA (1981) Anatomy of the kidney. In: Brenner Rectors (eds) The kidney. Saunders, Philadelphia, pp 28-35
12. Hayes DM, Cvitkovic E, Goldberg RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine chloride. Cancer 39:1372-1381
13. Higby DJ, Wallace HJ Jr, Albert DJ, Holland JF (1974) Diaminodichloroplatinum: a phase-I study showing responses in testicular and other tumors. Cancer 33:1219-1225
14. Al-Sarraf M, Fletcher W, Oishi N (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 66:31-35
15. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357-1361
16. Ostrow O, Egorin MJ, Hahn D (1981) High dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73-78
17. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssai PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44:164-172
18. Sobrero A, Guglemi A, Aschele C, Rosso R (1990) Current strategies to reduce cisplatin toxicity. J Chemother 2:3-7
19. Chary KK, Higby DJ, Henderson ES (1977) Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep 61:367-370
20. Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pretreatment on clinical, morphological, and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393-1399
21. Gehr M, Chopra S, Kaufman J, Chase D, Fjlamenbaum W (1981) The effect of furosemide on cis-diamminedichloroplatinum-induced acute renal failure. Kidney Int 19:201-204
22. Ward JM, Grabin ME, LeRoy AF, Young DM (1977) Modification of the renal toxicity of cis-diamminedichloroplatinum (II) with furosemide in male F344 rats. Cancer Treat Rep 61:375-379
23. Fisher DS, Knobf MT, Durivage HJ (1989) The cancer chemotherapy handbook, 4th edn. Mosby Yearbook, St. Louis
24. Anad AJ, Bashey B (1993) Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27:1519-1525
25. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III & IV ovarian cancer. J Clin Oncol 10:706-717
26. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112
27. Levey AS, Perrone RD, Madias NE (1988) Serum creatinine and renal function. Annu Rev Med 39:465-490
28. Daugaard G, Rossing N, Rorth M (1988) Effects of high dose cisplatin on glomerular function in the human kidney. Cancer Chemother Pharmacol 21:163-167